HER2免疫组织化学评分在富集的HER2--表达乳腺癌队列中的HER2免疫组织化学评分的可重复性
Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort
影响因子:1.90000
分区:医学4区 / 病理学3区
发表日期:2023 May 02
作者:
Cansu Karakas, Haley Tyburski, Bradley M Turner, Xi Wang, Linda M Schiffhauer, Hani Katerji, David G Hicks, Huina Zhang
摘要
我们评估了HER2免疫组织化学评分在富集的Her2-low表达乳腺癌的同伴中的观察者间和室内抗体的可重复性。总共114个乳腺癌标本被Herpectest（Agilent Dako）（Agilent Dako）和Pathway Anti-Her2（4B5）（VITANA）抗体抗体和Scornolines scority Hersanterate Hersantical sartrancity Hersanterals染色。通过COHENκ分析评估了一致性水平。尽管两种抗体的观察者间一致性率都达到了实质性一致，但赫斯蒂斯特的平均一致性率显着高于4B5克隆（74.3％vs 65.1％； p = .002）。两种抗体之间的总体室内抗体一致率为57.8％。在赫蒂斯特（Herceptest）的44.7％的病例中，在44.7％的案件中获得了完全观察者的一致性，而45.6％的案件为4B5。绝对协议率从HER2 0-1案件（赫蒂斯特的78.1％，4B5的72.2％；中度同意）增加到2-3例（91.9％，赫斯蒂斯特（Herpectest）为86.3％，到4B5的86.3％；几乎是完美的一致性）。您的结果表明，在评估Her2 Immuno Inscorsover in Cressover中，尤其是在评估术语中，尤其是在范围内进行了显着变化，尤其是在评估中，尤其是在评估中，尤其如此乳房专业的病理学家对Her2-low概念的认识。需要更准确和可重现的方法来选择可能受益于在Her2-lover乳腺癌上新认可的Her2靶向剂中受益的患者。
Abstract
We assessed the interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low-expressing breast cancer cohort.A total of 114 breast cancer specimens were stained by HercepTest (Agilent Dako) and PATHWAY anti-HER2 (4B5) (Ventana) antibody assays and scored by 6 breast pathologists independently using current HER2 guidelines. Level of agreement was evaluated by Cohen κ analysis.Although the interobserver agreement rate for both antibodies achieved substantial agreement, the average rate of agreement for HercepTest was significantly higher than that for the 4B5 clone (74.3% vs 65.1%; P = .002). The overall interantibody agreement rate between the 2 antibodies was 57.8%. Complete interobserver concordance was achieved in 44.7% of cases by HercepTest and 45.6% of cases by 4B5. Absolute agreement rates increased from HER2 0-1+ cases (78.1% by HercepTest and 72.2% by 4B5; moderate agreement) to 2-3+ cases (91.9% by HercepTest and 86.3% by 4B5; almost perfect agreement).Our results demonstrated notable interobserver and interantibody variation on evaluating HER2 immunohistochemistry, especially in cases with scores of 0-1+, although the performance was much more improved among breast-specialized pathologists with the awareness of HER2-low concept. More accurate and reproducible methods are needed for selecting patients who may benefit from the newly approved HER2-targeting agent on HER2-low breast cancers.